Subsequent female breast cancer risk associated with anthracycline chemotherapy for childhood cancer.

Wang, Yuehan; Ronckers, Cécile M; van Leeuwen, Flora E; Moskowitz, Chaya S; Leisenring, Wendy; Armstrong, Gregory T; de Vathaire, Florent; Hudson, Melissa M; Kuehni, Claudia E; Arnold, Michael A; Demoor-Goldschmidt, Charlotte; Green, Daniel M; Henderson, Tara O; Howell, Rebecca M; Ehrhardt, Matthew J; Neglia, Joseph P; Oeffinger, Kevin C; van der Pal, Helena J H; Robison, Leslie L; Schaapveld, Michael; ... (2023). Subsequent female breast cancer risk associated with anthracycline chemotherapy for childhood cancer. Nature medicine, 29(9), pp. 2268-2277. Springer Nature 10.1038/s41591-023-02514-1

Preview

Text s41591-023-02514-1.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (3MB) | Preview

Anthracycline-based chemotherapy is associated with increased subsequent breast cancer (SBC) risk in female childhood cancer survivors, but the current evidence is insufficient to support early breast cancer screening recommendations for survivors treated with anthracyclines. In this study, we pooled individual patient data of 17,903 survivors from six well-established studies, of whom 782 (4.4%) developed a SBC, and analyzed dose-dependent effects of individual anthracycline agents on developing SBC and interactions with chest radiotherapy. A dose-dependent increased SBC risk was seen for doxorubicin (hazard ratio (HR) per 100 mg m-2: 1.24, 95% confidence interval (CI): 1.18-1.31), with more than twofold increased risk for survivors treated with ≥200 mg m-2 cumulative doxorubicin dose versus no doxorubicin (HR: 2.50 for 200-299 mg m-2, HR: 2.33 for 300-399 mg m-2 and HR: 2.78 for ≥400 mg m-2). For daunorubicin, the associations were not statistically significant. Epirubicin was associated with increased SBC risk (yes/no, HR: 3.25, 95% CI: 1.59-6.63). For patients treated with or without chest irradiation, HRs per 100 mg m-2 of doxorubicin were 1.11 (95% CI: 1.02-1.21) and 1.26 (95% CI: 1.17-1.36), respectively. Our findings support that early initiation of SBC surveillance may be reasonable for survivors who received ≥200 mg m-2 cumulative doxorubicin dose and should be considered in SBC surveillance guidelines for survivors and future treatment protocols.

Interest & Impact

Downloads

2 since deposited on 14 Sep 2023
2 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item